Serum progesterone levels in patients with gastric adenocarcinoma before and after gastrectomy

Chew Wun Wu, Chin Wen Chi, Mao Chih Hsieh, Su Shun Lo, King Han Shen, Wing Yiu Lui, Fang Ku P'eng

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BACKGROUND. Having observed that progesterone receptors exist in all gastric carcinoma tissues, the authors determined that serum progesterone levels in gastric carcinoma patients were worthy of evaluation. METHODS. Serum progesterone levels were determined in patients with gastric adenocarcinoma and in patients with benign disease who served as controls. All female patients were older than 55 years. The clinicopathologic significance of their serum progesterone levels was determined. RESULTS. In male patients (n = 122), the serum progesterone level (mean ± standard deviation) was significantly higher than in the male control group (n = 163) (0.264 ± 0.261 vs. 0.142 ± 0.113 ng/mL; P <0.001) and showed a tendency to be stage-related (P = 0.029). Serum progesterone levels significantly decreased after gastrectomy in patients with disease at Stage I (n = 27), II (n = 20), and III (n = 32), but not IV (n = 7). In 11 patients who died of recurrence, the serum progesterone levels were decreased when they were disease free but raised when recurrence was clinically evident. Patients with serum progesterone levels >0.264 ng/mL survived for significantly shorter periods than those with levels ≤0.264 ng/mL (P = 0.039). However, serum progesterone level was not an independent predictor of survival. Among the female patients (n = 12), the serum progesterone level (mean ± standard deviation) of patients with gastric carcinoma was 0.427 ± 0.428 ng/mL, whereas that of the control group (n = 17) was 0.217 ± 0.451 ng/mL; the difference was statistically significant (P = 0.02). In female disease free patients studied postoperatively, the progesterone after gastrectomy showed a tendency to decrease, but this difference was not statistically significant (0.444 ± 0.368 vs. 0.175 ± 0.150 ng/mL; P = 0.091; n = 7). CONCLUSIONS. These data suggest that serum progesterone level reflects the presence or absence of gastric carcinoma by some unknown mechanism.

Original languageEnglish
Pages (from-to)445-448
Number of pages4
JournalCancer
Volume83
Issue number3
DOIs
Publication statusPublished - Aug 1 1998

Fingerprint

Gastrectomy
Progesterone
Stomach
Adenocarcinoma
Serum
Carcinoma
Control Groups
Progesterone Receptors
Survival

Keywords

  • Gastrectomy
  • Gastric adenocarcinoma
  • Recurrence
  • Serum progesterone

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Serum progesterone levels in patients with gastric adenocarcinoma before and after gastrectomy. / Wu, Chew Wun; Chi, Chin Wen; Hsieh, Mao Chih; Lo, Su Shun; Shen, King Han; Lui, Wing Yiu; P'eng, Fang Ku.

In: Cancer, Vol. 83, No. 3, 01.08.1998, p. 445-448.

Research output: Contribution to journalArticle

Wu, Chew Wun ; Chi, Chin Wen ; Hsieh, Mao Chih ; Lo, Su Shun ; Shen, King Han ; Lui, Wing Yiu ; P'eng, Fang Ku. / Serum progesterone levels in patients with gastric adenocarcinoma before and after gastrectomy. In: Cancer. 1998 ; Vol. 83, No. 3. pp. 445-448.
@article{5b41f036344f439bbbfc4dd611c4b32c,
title = "Serum progesterone levels in patients with gastric adenocarcinoma before and after gastrectomy",
abstract = "BACKGROUND. Having observed that progesterone receptors exist in all gastric carcinoma tissues, the authors determined that serum progesterone levels in gastric carcinoma patients were worthy of evaluation. METHODS. Serum progesterone levels were determined in patients with gastric adenocarcinoma and in patients with benign disease who served as controls. All female patients were older than 55 years. The clinicopathologic significance of their serum progesterone levels was determined. RESULTS. In male patients (n = 122), the serum progesterone level (mean ± standard deviation) was significantly higher than in the male control group (n = 163) (0.264 ± 0.261 vs. 0.142 ± 0.113 ng/mL; P <0.001) and showed a tendency to be stage-related (P = 0.029). Serum progesterone levels significantly decreased after gastrectomy in patients with disease at Stage I (n = 27), II (n = 20), and III (n = 32), but not IV (n = 7). In 11 patients who died of recurrence, the serum progesterone levels were decreased when they were disease free but raised when recurrence was clinically evident. Patients with serum progesterone levels >0.264 ng/mL survived for significantly shorter periods than those with levels ≤0.264 ng/mL (P = 0.039). However, serum progesterone level was not an independent predictor of survival. Among the female patients (n = 12), the serum progesterone level (mean ± standard deviation) of patients with gastric carcinoma was 0.427 ± 0.428 ng/mL, whereas that of the control group (n = 17) was 0.217 ± 0.451 ng/mL; the difference was statistically significant (P = 0.02). In female disease free patients studied postoperatively, the progesterone after gastrectomy showed a tendency to decrease, but this difference was not statistically significant (0.444 ± 0.368 vs. 0.175 ± 0.150 ng/mL; P = 0.091; n = 7). CONCLUSIONS. These data suggest that serum progesterone level reflects the presence or absence of gastric carcinoma by some unknown mechanism.",
keywords = "Gastrectomy, Gastric adenocarcinoma, Recurrence, Serum progesterone",
author = "Wu, {Chew Wun} and Chi, {Chin Wen} and Hsieh, {Mao Chih} and Lo, {Su Shun} and Shen, {King Han} and Lui, {Wing Yiu} and P'eng, {Fang Ku}",
year = "1998",
month = "8",
day = "1",
doi = "10.1002/(SICI)1097-0142(19980801)83:3<445::AID-CNCR12>3.0.CO;2-W",
language = "English",
volume = "83",
pages = "445--448",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Serum progesterone levels in patients with gastric adenocarcinoma before and after gastrectomy

AU - Wu, Chew Wun

AU - Chi, Chin Wen

AU - Hsieh, Mao Chih

AU - Lo, Su Shun

AU - Shen, King Han

AU - Lui, Wing Yiu

AU - P'eng, Fang Ku

PY - 1998/8/1

Y1 - 1998/8/1

N2 - BACKGROUND. Having observed that progesterone receptors exist in all gastric carcinoma tissues, the authors determined that serum progesterone levels in gastric carcinoma patients were worthy of evaluation. METHODS. Serum progesterone levels were determined in patients with gastric adenocarcinoma and in patients with benign disease who served as controls. All female patients were older than 55 years. The clinicopathologic significance of their serum progesterone levels was determined. RESULTS. In male patients (n = 122), the serum progesterone level (mean ± standard deviation) was significantly higher than in the male control group (n = 163) (0.264 ± 0.261 vs. 0.142 ± 0.113 ng/mL; P <0.001) and showed a tendency to be stage-related (P = 0.029). Serum progesterone levels significantly decreased after gastrectomy in patients with disease at Stage I (n = 27), II (n = 20), and III (n = 32), but not IV (n = 7). In 11 patients who died of recurrence, the serum progesterone levels were decreased when they were disease free but raised when recurrence was clinically evident. Patients with serum progesterone levels >0.264 ng/mL survived for significantly shorter periods than those with levels ≤0.264 ng/mL (P = 0.039). However, serum progesterone level was not an independent predictor of survival. Among the female patients (n = 12), the serum progesterone level (mean ± standard deviation) of patients with gastric carcinoma was 0.427 ± 0.428 ng/mL, whereas that of the control group (n = 17) was 0.217 ± 0.451 ng/mL; the difference was statistically significant (P = 0.02). In female disease free patients studied postoperatively, the progesterone after gastrectomy showed a tendency to decrease, but this difference was not statistically significant (0.444 ± 0.368 vs. 0.175 ± 0.150 ng/mL; P = 0.091; n = 7). CONCLUSIONS. These data suggest that serum progesterone level reflects the presence or absence of gastric carcinoma by some unknown mechanism.

AB - BACKGROUND. Having observed that progesterone receptors exist in all gastric carcinoma tissues, the authors determined that serum progesterone levels in gastric carcinoma patients were worthy of evaluation. METHODS. Serum progesterone levels were determined in patients with gastric adenocarcinoma and in patients with benign disease who served as controls. All female patients were older than 55 years. The clinicopathologic significance of their serum progesterone levels was determined. RESULTS. In male patients (n = 122), the serum progesterone level (mean ± standard deviation) was significantly higher than in the male control group (n = 163) (0.264 ± 0.261 vs. 0.142 ± 0.113 ng/mL; P <0.001) and showed a tendency to be stage-related (P = 0.029). Serum progesterone levels significantly decreased after gastrectomy in patients with disease at Stage I (n = 27), II (n = 20), and III (n = 32), but not IV (n = 7). In 11 patients who died of recurrence, the serum progesterone levels were decreased when they were disease free but raised when recurrence was clinically evident. Patients with serum progesterone levels >0.264 ng/mL survived for significantly shorter periods than those with levels ≤0.264 ng/mL (P = 0.039). However, serum progesterone level was not an independent predictor of survival. Among the female patients (n = 12), the serum progesterone level (mean ± standard deviation) of patients with gastric carcinoma was 0.427 ± 0.428 ng/mL, whereas that of the control group (n = 17) was 0.217 ± 0.451 ng/mL; the difference was statistically significant (P = 0.02). In female disease free patients studied postoperatively, the progesterone after gastrectomy showed a tendency to decrease, but this difference was not statistically significant (0.444 ± 0.368 vs. 0.175 ± 0.150 ng/mL; P = 0.091; n = 7). CONCLUSIONS. These data suggest that serum progesterone level reflects the presence or absence of gastric carcinoma by some unknown mechanism.

KW - Gastrectomy

KW - Gastric adenocarcinoma

KW - Recurrence

KW - Serum progesterone

UR - http://www.scopus.com/inward/record.url?scp=0032146972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032146972&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19980801)83:3<445::AID-CNCR12>3.0.CO;2-W

DO - 10.1002/(SICI)1097-0142(19980801)83:3<445::AID-CNCR12>3.0.CO;2-W

M3 - Article

VL - 83

SP - 445

EP - 448

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -